BE638140A - - Google Patents
Info
- Publication number
- BE638140A BE638140A BE638140DA BE638140A BE 638140 A BE638140 A BE 638140A BE 638140D A BE638140D A BE 638140DA BE 638140 A BE638140 A BE 638140A
- Authority
- BE
- Belgium
- Prior art keywords
- emi
- pharmaceutical preparation
- volume
- treatment
- oral
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000000243 solution Substances 0.000 description 4
- WPKQVDYSPWCVGM-UHFFFAOYSA-N (3beta,5beta)-3-[(2,6-dideoxy-3-O-methyl-beta-D-ribo-hexopyranosyl)oxy]-5,14,19-trihydroxycard-20(22)-enolide Natural products O1C(C)C(O)C(OC)CC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CCC3C2(CO)CC1 WPKQVDYSPWCVGM-UHFFFAOYSA-N 0.000 description 3
- WPKQVDYSPWCVGM-ZNDDOCHDSA-N 3-[(3S,5S,8R,9S,10R,13R,14S,17R)-5,14-dihydroxy-3-[(2R,4S,5R,6R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10-(hydroxymethyl)-13-methyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one Chemical compound O1[C@H](C)[C@@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(CO)CC1 WPKQVDYSPWCVGM-ZNDDOCHDSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XQCGNURMLWFQJR-ZNDDOCHDSA-N Cymarin Chemical compound O1[C@H](C)[C@@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(C=O)CC1 XQCGNURMLWFQJR-ZNDDOCHDSA-N 0.000 description 2
- XQCGNURMLWFQJR-UESCRGIISA-N Cymarin Natural products O=C[C@@]12[C@@](O)(C[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)CC[C@H]21 XQCGNURMLWFQJR-UESCRGIISA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 229960003083 cymarin Drugs 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- -1 solutes Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB37529/62A GB1075251A (en) | 1962-10-04 | 1962-10-04 | Cardenolide derivatives |
| GB3251263 | 1963-08-16 | ||
| GB3251163 | 1963-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE638140A true BE638140A (en:Method) |
Family
ID=27259055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE638140D BE638140A (en:Method) | 1962-10-04 |
Country Status (10)
| Country | Link |
|---|---|
| BE (1) | BE638140A (en:Method) |
| CH (3) | CH428721A (en:Method) |
| DE (1) | DE1593722C3 (en:Method) |
| DK (3) | DK111175B (en:Method) |
| ES (1) | ES291954A1 (en:Method) |
| FI (2) | FI40459B (en:Method) |
| LU (1) | LU44568A1 (en:Method) |
| MC (1) | MC436A1 (en:Method) |
| NL (1) | NL298322A (en:Method) |
| SE (3) | SE318272B (en:Method) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5897107A (en) * | 1997-02-24 | 1999-04-27 | Horton, Inc. | Roller bushing assembly |
-
0
- NL NL298322D patent/NL298322A/xx unknown
- BE BE638140D patent/BE638140A/fr unknown
-
1963
- 1963-09-25 ES ES291954A patent/ES291954A1/es not_active Expired
- 1963-09-27 CH CH1273266A patent/CH428721A/de unknown
- 1963-09-27 CH CH1191963A patent/CH431510A/de unknown
- 1963-09-27 FI FI188463A patent/FI40459B/fi active
- 1963-09-27 CH CH1492366A patent/CH433277A/de unknown
- 1963-09-30 DE DE19631593722 patent/DE1593722C3/de not_active Expired
- 1963-10-03 MC MC458A patent/MC436A1/xx unknown
- 1963-10-03 DK DK466163A patent/DK111175B/da unknown
- 1963-10-04 LU LU44568D patent/LU44568A1/xx unknown
- 1963-10-04 SE SE1086163A patent/SE318272B/xx unknown
-
1965
- 1965-03-17 DK DK136265A patent/DK113499B/da unknown
-
1966
- 1966-03-28 SE SE4065/66A patent/SE324151B/xx unknown
- 1966-11-25 SE SE1614166A patent/SE318560B/xx unknown
- 1966-12-20 DK DK658466A patent/DK114831B/da unknown
-
1968
- 1968-03-15 FI FI71868A patent/FI41551B/fi active
Also Published As
| Publication number | Publication date |
|---|---|
| DE1593722B2 (de) | 1974-04-04 |
| NL298322A (en:Method) | |
| DE1593722C3 (de) | 1974-11-07 |
| CH428721A (de) | 1967-01-31 |
| DE1593722A1 (de) | 1970-12-03 |
| DK114831B (da) | 1969-08-11 |
| SE318560B (en:Method) | 1969-12-15 |
| DK113499B (da) | 1969-03-31 |
| FI40459B (en:Method) | 1968-10-31 |
| MC436A1 (fr) | 1964-07-06 |
| SE324151B (en:Method) | 1970-05-25 |
| DK111175B (da) | 1968-06-24 |
| CH433277A (de) | 1967-04-15 |
| CH431510A (de) | 1967-03-15 |
| FI41551B (en:Method) | 1969-09-01 |
| LU44568A1 (en:Method) | 1964-04-04 |
| SE318272B (en:Method) | 1969-12-08 |
| ES291954A1 (es) | 1963-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2661011C2 (de) | 17ß-Ester von Östradiol | |
| US4083973A (en) | Pharmaceutical preparation adapted for oral administration | |
| Selye | Protection by a steroid-spirolactone against certain types of cardiac necroses. | |
| US4260603A (en) | Sterol glycoside with activity as prostaglandin synthetase inhibitor | |
| FR2532844A1 (fr) | Composition pharmaceutique contenant un compose polyprenylique | |
| KR880003626A (ko) | 레트로비루스로 감염된 환자의 치료에 있어서의 2',3'-디디옥시사이티딘-2'-엔(2',3'-디디옥시-2',3'-디디하이드로사이티딘)의 사용법 | |
| JPH02174719A (ja) | ステロリンおよび／またはスピロケタリンを含有する経皮投与用医薬組成物 | |
| GB2039217A (en) | Anti-inflammatory medicaments comprising glycosides of sterols or spiroketal steroids or esters thereof | |
| DE2818164A1 (de) | 1,3-dibenzoesaeureester des 17alpha- ethinyl-7 alpha -methyl-1,3,5(10)-oestratrien- 1,3,17 beta -triols, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| BE638140A (en:Method) | ||
| US4265886A (en) | Spiroketalins and their applications | |
| ATE1066T1 (de) | Aminopropanolderivate des 6-hydroxy-2,3,4,5-tetrahy dro-1h-1-benzazepin-2-ons, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. | |
| US3211617A (en) | Heparine derivatives and process for preparation and utilization | |
| Schwenk et al. | Experiments on cholesterol atherosclerosis in rabbits. | |
| Pasqualini et al. | STUDIES ON THE METABOLISM OF CORTICOSTEROIDS IN THE HUMAN FOETO-PLACENTAL UNIT: 2. Corticosterone metabolism in previable foetuses | |
| US2824044A (en) | Process for the manufacture of 11-hydroxy steroid compounds | |
| GB2024624A (en) | Anti inflammatory spiroketalins | |
| JPS61145177A (ja) | カテキン誘導体 | |
| Pearlman et al. | The Preparation of 3, 4, 5-d 3-Lithocholic Acid | |
| US3641013A (en) | 17beta-hydroxy-18-methyl-4-estrene-3-one and derivatives thereof | |
| US4461763A (en) | Oximes of 3'"-dehydrocardenolide tridigitoxosides | |
| FR2417M (en:Method) | ||
| AT333980B (de) | Verfahren zur herstellung von neuen dihydrodigoxin-derivaten | |
| ATE965T1 (de) | Aminopropanolderivate des 2-(o-hydroxyphenyl)-pyrrols, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. | |
| AU592708B2 (en) | Injection containing 3-benzoyloxy-1,3,5(10)-estratriene-17-(4-{p-(bis(2- chloroethyl)amino)phenyl}-butanoyloxy)acetate as an active ingredient |